Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Sohel_Parvez_Haque/iStock via Getty Images Exelixis, (EXEL) down 6% premarket and Ipsen (IPSEY) announce that Phase 3 COSMIC-312 trial evaluating cabozantinib (Cabometyx) in combination with Roche's (RHHBY) atezolizumab vs. sorafenib in patients with previously untreated advanced he...
Regulatory News: Exelixis, Inc. (NASDAQ: EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced that COSMIC-312, the ongoing phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab versus sorafenib in patients with previously untreat...
Ipsen analyzed data held in two large U.S. medical insurance databases, amounting to over 15 million patients, including nearly 1.3 million people living with active spasticity 1 Despite being a recommended first-line treatment, only 3-4% of eligible adults living with active ...
– New findings demonstrate the significant progression-free survival benefit seen in the intent-to-treat population was also consistent across subgroups – – Results from COSMIC-311 served as basis for Exelixis’ recent supplemental New Drug App...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty biopharmaceutical group, announces the launch of an Employee Shareholding plan. This third transaction in the last five years, aims to involve Ipsen's employees more closely, both in France and abroad, in the...
Ipsen ([[IPSEY]] -6.7%) announces that its New Drug Application ((NDA)) for palovarotene as a potential treatment option for people living with the progressive disabling and ultra-rare genetic disorder fibrodysplasia ossificans progressiva ((FOP)), has been accepted by the U.S. FDA.The target...
New Drug Application granted Priority Review status, with a decision anticipated on 30 November 2021 European Medicines Agency (EMA) and Swissmedic have also validated the Marketing Authorization Application (MAA) for palovarotene with Swissmedic granting palovarotene a priority r...
The pharmaceutical sector received much investor attention amid the COVID-19 pandemic and their interest in this sector is expected to continue given the growing demand for pharmaceutical products and solutions. As such, we think it could be smart to bet on relatively undervalued pharma stock...
Ipsen (IPSEY) has exercised its option to collaborate with Exelixis (EXEL) in a pivotal trial for Cabometyx (cabozantinib) in patients with radioiodine-refractory differentiated thyroid cancer ((DTC)).Following the exercise of the option, Ipsen which already has an exclusive partner...
Opt-in decision is based on interim results from the pivotal COSMIC-311 Phase III trial in people living with radioiodine-refractory differentiated thyroid cancer 1 Detailed results will be presented at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meet...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...